Eli Lilly Stock Splits and Growth Prospects

Eli Lilly has a history of stock splits, with the most recent one occurring in 2021, where the company split its stock 4-for-1. This move increased the liquidity of the stock and made it more accessible to individual investors.

The company's growth prospects are fueled by its diverse portfolio of medications, including insulin, cancer treatments, and mental health medications. Eli Lilly has a strong pipeline of new products in development.

In 2019, Eli Lilly acquired Loxo Oncology, a biotech company focused on cancer treatments, for $8 billion. This acquisition expanded Eli Lilly's presence in the oncology market.

Eli Lilly has a history of investing in research and development, with a focus on innovative treatments for complex diseases.

A different take: Lilly Stock Symbol

Eli Lilly's stock price is currently around $902.04, and analysts see a 25.86% upside with an average price target of $1,127.67.

Several analysts have given Eli Lilly a Buy rating, including Citigroup, Bernstein, and Truist Securities, which implies a significant price increase. This rating is based on the company's strong demand for its products and its potential for continued revenue and earnings growth.

Explore further: Stock Price

Eli Lilly has had four previous 2-for-1 forward stock splits in the past, with the last one occurring 27 years ago. This history suggests that the company may be due for another split to make its stock more accessible to retail investors.

Here's a breakdown of the analyst ratings and price targets for Eli Lilly:

Eli Lilly Stock has undergone several stock splits in its history. The first stock split occurred in 1964, with a 2-for-1 ratio, increasing the number of outstanding shares.

In 1987, Eli Lilly Stock split 2-for-1 again, doubling the number of shares. This was followed by a 2-for-1 split in 1994, further increasing the number of shares available to investors.

Eli Lilly Stock has a history of stable growth, with a consistent track record of increasing its dividend payments. The company has maintained this trend, with a current dividend yield of around 2%.

The most recent stock split occurred in 2008, with a 2-for-1 ratio, bringing the total number of shares to over 1.5 billion. This move was likely aimed at making the stock more accessible to a wider range of investors.

Take a look at this: Share Split History

Eli Lilly stock has been making headlines lately, and for good reason. Analysts are predicting a 25.86% upside for Eli Lilly, with an average price target of $1,127.67.

The consensus analyst rating on Eli Lilly stock is currently a Buy, with a price target of $927.42. This suggests that many experts believe the stock has significant growth potential.

Eli Lilly has a history of forward stock splits, with four previous 2-for-1 splits in 1986, 1989, 1995, and 1997. It's been 27 years since the last split, which could justify a new split soon.

The company's strong demand for its products, particularly Mounjaro and Zepbound, could also support a stock split. In fact, growth from these sales alone can justify continued revenue and earnings growth.

The potential for a stock split is further supported by the fact that Eli Lilly did not have a widely distributed mRNA-based vaccine, which could reduce its liability compared to rivals like Pfizer and Moderna.

Consider reading: Stock Splits with Growth Potential

Here's a summary of the analyst ratings and price targets for Eli Lilly stock:

Eli Lilly's stock price is currently trading flat at $902.04, but with a strong demand for its products and a history of forward stock splits, it's likely that the stock will continue to grow in the future.